Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DARTBOARD: Daily Adaptive Radiotherapy in Head and Neck Cancer
NCT04883281Phase 2Completed
- Sponsor
- UT Southwestern Medical Center
- Start
- Feb 2022
- Primary completion
- Sep 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by UT Southwestern Medical Center. Primary endpoint: Xerostomia Questionnaire at 1 year. Started Feb 2022; status: completed.
02
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04883281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04883281.